4.7 Article

Self-delivery nanomedicine for vascular disruption-supplemented chemo-photodynamic tumor therapy

期刊

JOURNAL OF COLLOID AND INTERFACE SCIENCE
卷 612, 期 -, 页码 562-571

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.jcis.2021.12.128

关键词

Self-delivery; Vascular disruption; Photodynamic therapy; Nanomedicine; Self-assembly

资金

  1. National Natural Science Foundation of China [52073140, 51803086]
  2. Guangdong Basic and Applied Basic Research Foundation [2021A1515010418, 2021B1515020043]
  3. Project of Educational Commission of Guangdong Province [2018KTSCX190]
  4. Natural Science Foundation of Guangdong Province [2018A030313593]
  5. Science and Technology Programs of Guangzhou [201904010324, 202002030178]
  6. Open Research Foundation of State Key Laboratory of Respiratory Diseases [SKLRD-OP-202204]
  7. Young Elite Scientist Sponsorship Program by CAST [2018QNRC001]

向作者/读者索取更多资源

A self-delivery nanomedicine based on a vascular disruptor and photosensitizer has been developed for synergistic tumor therapy. This nanomedicine can inhibit tumor growth through chemotherapy and photodynamic therapy, with low side effects in vivo.
Tumor vascular blockade is a promising strategy for adjuvant cancer treatment. In this work, a selfdelivery nanomedicine is developed based on a vascular disruptor and photosensitizer for tumor synergistic therapy. Specifically, this nanomedicine (designated as CeCA) is comprised of combretastatin A4 (CA4) and chlorine e6 (Ce6) by self-assembly technique. Among which, CA4 could not only induce tubulin inhibition for chemotherapy but also disrupt the vasculature to cause tumor hemorrhage. Moreover, Ce6 is able to generate lots of singlet oxygen (1O2) for synergistic photodynamic therapy (PDT) under light irradiation. It is interesting that the carrier-free CeCA possessed a favorable stability and an improved cellular uptake behavior. After intravenous administration, CeCA prefers to accumulate at tumor site for vascular disruption-supplemented chemo-photodynamic therapy. Notably, CeCA is prepared without additional carriers, which avoids the system toxicity raised by excipients. Consequently, CeCA greatly inhibits the tumor growth and leads to a low side effect in vivo. It might open a window in the development of self-supplementary nanomedicine for synergistic tumor treatment. (c) 2021 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据